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Alcoholic liver disease (ALD) andnonalcoholic fatty liver dis-
ease (NAFLD) representmain causes of chronic liver disorder
in the Western countries. Both ALD and NAFLD include a
wide spectrum of conditions ranging from “simple” steatosis
to steatohepatitis, cirrhosis, and hepatocellular carcinoma.
ALDandNAFLD, besides sharingmanyhistological patterns,
have in common a negative impact on both cardiovascular
and cancer risk. Consequently, ALD and NAFLD should be
considered not only liver diseases but also systemic condi-
tions that harmfully influence both morbidity and mortality.
ALD is caused by acute and/or chronic alcohol intake
while NAFLD is outlined as the presence of hepatic steatosis
without other causes of secondary fat accumulation such as
noteworthy alcohol consumption and hereditary disorders.
NAFLD is a complex illness with genetic and environmental
risk factors and is typically coupledwithmetabolic conditions
such as obesity and diabetes.
In this special issue, we present original research as
well as review articles on the following topics: relationship
between gut-liver axis and NAFLD, diagnostic ability of
transient elastography inNAFLD (and simultaneous hepatitis
B virus), noninvasive markers of fibrosis in ALD, NAFLD,
and pancreas damage, role of traditional Chinese Medicine
in the treatment of NAFLD, and use of antifibrotic drug for
the cure of liver disease.
Recent advances demonstrated that microbiota shows a
key role in many kinds of diseases. In particular, microbiota
dysbiosis seems to be involved in the pathogenesis of nonal-
coholic steatohepatitis (NASH) that definitely represents the
progressive form of NAFLD. Modifications of microbiota-
derived mediators, alterations of gut endothelial barrier, and
translocation of inflammation mediators could negatively
influence the outcome of liver damage due to NASH. G.
Aragonès et al., with a whole review article, discuss the role
of gut microbiota-derived mediators as potential diagnostic
markers of NAFLD and NASH. The article underlines the
relevance of developing noninvasive tools for the screening
and diagnosis of NAFLD since the current gold standard
(liver biopsy) shows some well-known limits related to safety,
compliance, and feasibility. In particular, liver biopsy can
lead to complications such as bleeding, pain, bile peritonitis,
kidney puncture, or death. Furthermore, sampling errors
are common due to effort with obtaining liver specimen
representative of the entire organ. In the present special
issue, other data about noninvasive diagnosis of NAFLD
are reported. Specifically, the concordance between transient
elastography (TE) and ultrasonography (US) in assessing
liver fibrosis in patients with both chronic hepatitis B (CHB)
and NAFLD is evaluated. Using the liver biopsy as standard
comparison, G. Zhang et al. demonstrated that TE and US
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scores knowingly correlated with histologically proven liver
fibrosis.
Obviously, also in patients with ALD to develop noninva-
sive methods of diagnosis would be important. L. Chrostek et
al. analyzed the diagnostic values of the followingnoninvasive
indirect markers of liver fibrosis: APRI, GAPRI, Forn’s, FIB-
4, Age-Platelet, andHepascore in patients with ALD. Authors
suggested that Hepascore showed lower diagnostic value in
alcoholics thanmarkers involving only liver enzymes, platelet
count, and cholesterol. Remarkably, Forn’s index emerged as
the best marker among those analyzed.
The relationship between NAFLD and systemic dam-
age is widely known particularly regarding cardiovascular
risk. However, few data are available about the pathological
relationship between NAFLD and pancreatitis. Abdominal
obesity represents a chief element in the NAFLD patho-
genesis and, at the same time, it can be a risk factor for
acute pancreatitis. Interestingly, D. Wu et al. reported that
NAFLD could exacerbate pancreatitis through releasing a
large number of inflammatory factors. Notably, Kupffer cells
(the resident macrophages of the liver) primarily mediate the
NAFLD-related chronic inflammatory process.
The complexity of NAFLD and NASH pathogenesis
explains the difficulties of scientific community in the devel-
opment of widely approved effective treatment. The presence
of parallel “hit” explains the systemic impact of NAFLD and
the opportunity to develop drugs that can act on multiple
levels. Y. Feng et al., conceptually in agreement with this
concept, developed an animal study with the use of Jianpi
Huoxue (JPHX) as treatment of NAFLD. The proposed
Chinese herbal formula holds active compounds that regulate
lipid metabolism and shows anti-inflammatory properties.
JPHX exhibited hepatoprotective effects in animals with
severe livery injuries (steatosis, inflammation, and fibrosis)
decreasing lipid accumulation, inflammation, apoptosis, and
fibrosis.
The main limitation of the available studies describing
the treatment options for the treatment of NAFLD is the
lack of a relevant effect on the fibrosis. In this direction, M.
M. Arafah et al. planned a study using a rat model of liver
fibrosis (obtained with intraperitoneal injections of carbon
tetrachloride). A total of 45 rats were divided into 3 groups:
control group, group II that received carbon tetrachloride
for 8 weeks, and group III that was treated with carbon
tetrachloride and nAG protein for the same time period. At
the end of the experiment, serum levels of hyaluronic acid,
PDGF-AB, TIMP-1, laminin, Procollagen III- N terminal
peptide, and collagen IV alpha 1 chain were tested and liver
biopsies were performed. NAG treatment decreased serum
levels of the analyzed markers of fibrosis reducing also the
histological fibrosis.
We believe that these articles may contribute to improve
our knowledge in ALD and NAFLD that definitely represent
the future of hepatology.
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